May 21, 2007 - VirtualScopics, Inc., a developer of image-based biomarker solutions, announced today that it released its next generation 2.0 software platform for the use of imaging in clinical trials, delivering operational efficiencies and enhanced reporting in order to expedite customers' clinical trial process.
"We are excited about the release of the 2.0 platform as it not only makes us more efficient in later stage clinical trials but also incorporates many features that our customers have requested relative to reporting and data mining. These enhancements provide our customers access to critical information earlier in the process, to further accelerate drug development," said Jeff Markin, president and chief executive officer of VirtualScopics, Inc. "This software release provides a solid platform for additional planned releases that will enhance our ability to provide real-time information to our customers on a global basis."
May 17, 2024 
